Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19

NEXT STORY
Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan
PREV STORY
Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure

HeartWare(TM) HVAD(TM) System Only LVAD Approved for Implant via Thoracotomy or Median Sternotomy DUBLIN ...

author_avatar
NASDAQ Market News

Cell-Based Assays Market Size To Reach USD 28.2 Billion In 2028; CAGR of 8.5%: Reports And Data

author_avatar
NASDAQ Market News

Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

author_avatar
NASDAQ Market News